Insulin, Neurogenetics and Memory in Alzheimer's Disease

Alzheimer Disease Clinical Trial

Official title:

Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00018382
• Other study ID #: AGCG-012-98S
• Status: Completed
• Phase: Phase 2
• First received: July 3, 2001
• Last updated: January 20, 2009
• Start date: October 1999
• Est. completion date: March 2003

Study information

• Verified date: December 2004
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: March 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 55 Years to 80 Years

Eligibility

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Drug:
• rosiglitazone

Locations

Country	Name	City	State
United States	VA Puget Sound Health Care System	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States,